36results about "Cyclosporins" patented technology

The present invention relates to solid state forms of lenicortafusp (RCF), pharmaceutical compositions comprising the solid state forms and methods of manufacturing pharmaceutical dosage forms utilizing the solid state forms.

This disclosure provides methods and reagents useful for analyzing protein-protein interfaces, such as the interface between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophyllin family, or PIN1) and a target protein. [Solution] In some embodiments, the target and / or presenter protein is an intracellular protein. In some embodiments, the target and / or presenter protein is a mammalian protein.

Compositions are disclosed that include acridinium esters of cyclosporin A or C. Kits containing same, as well as methods of making and using same, are also disclosed.

The present disclosure provides compounds defined by Formulae 1-6 and their use as cyclophilin inhibitors for the prevention or treatment of a disease or disorder, such as a cyclophilin-mediated disease or disorder, in particular a cyclophilin A-mediated disease or disorder.

To provide a new molecular modality capable of modulating the function of an undruggable target.SOLUTION: A compound (e.g., a macrocyclic compound comprising 14 to 40 ring atoms as shown below) capable of modulating a biological process by binding to presenter proteins (e.g., members of the FKBP family, members of the cyclophilin family, or PIN1) and target proteins (e.g., eukaryotic target proteins such as mammalian target proteins or fungal target proteins or prokaryotic target proteins such as bacterial target proteins).SELECTED DRAWING: None

A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus, (I).

Provided herein is Compound I or a pharmaceutically acceptable salt thereof for use in the prevention and / or treatment of a kidney condition or disease in a subject exposed to a nephrotoxin capable of inducing said kidney condition or disease.

This invention relates to the field of insect control, specifically to the Paecilomyces lilacinus strain XI-5, and the extraction and identification of crude toxins produced by secondary metabolites of Paecilomyces lilacinus strain XI-5. This invention confirms that the secondary metabolites of Paecilomyces lilacinus strain XI-5 produce cyclosporine C. Cyclosporine C has a stomach poison effect on adult whiteflies. Twenty-four hours after application, the LC50 concentration of cyclosporine C against adult whiteflies was 31.75 µg / ml; compared to the control group, the LC30 concentration of cyclosporine C resulted in a decrease in oviposition / fertility in female whiteflies.

Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.

Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, in particular diseases or conditions associated with cellular injury or cell death, such as organ injury or organ failure, which can be caused by a number of different reasons, such as ischemia or ischemia reperfusion injury, toxins, infection or mechanical trauma.

This article discloses cyclosporine compounds and methods for treating or preventing neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.

The invention relates to a process for the preparation of an intermediate useful for the synthesis of voclosporin, an immunosuppressant active ingredient inhibitor of calcineurin.

Compounds defined by Formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders, such as organ injury or organ failure.

This invention relates to solid state forms of Rencofilstat (RCF), pharmaceutical compositions comprising the same, and methods of manufacturing pharmaceutical dosage forms utilizing the same.

Compounds as defined by Formulas 1-6 and uses thereof for as cyclophilin inhibitors, for the prevention or treatment of diseases or conditions such as cyclophilin-mediated diseases or conditions, in particular, cyclophilin A-mediated diseases or conditions.

The compounds defined by formula 4 are used as cyclophilin inhibitors for the prevention or treatment of diseases or disorders such as organ injury or organ failure. JPEG2023518777000061.jpg77132

The present invention belongs to the technical field of drug synthesis. In particular, the present invention is related to a for preparing a salt of isocyclosporin A, in particular by transesterification of cyclosporin A into a salt of isocyclosporin A.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces, for example, the interface between a presenter protein (eg, a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and / or presenter proteins are intracellular proteins, hi some embodiments, the target and / or presenter proteins are mammalian proteins.

Use of cyclosporin H (CsH) or a derivative thereof for increasing the efficiency of transduction of an isolated population of cells by a viral vector and / or increasing the efficiency of gene editing of an isolated population of cells when transduced by a viral vector.

JPEG2022551161000018.jpg89145 Provided herein is Compound I or a pharmaceutically acceptable salt thereof for use in the prevention and / or treatment of a renal condition or disease in a subject exposed to a nephrotoxin that may induce the renal condition or disease.

Disclosed herein are ophthalmic pharmaceutical compositions, eye drop formulations, nanoparticle formulations, and liposome formulations comprising gabapentinoids for treating ocular neuropathic pain.

Methods and reagents useful for analyzing interfaces between target proteins are provided. [Solution] The present disclosure provides methods and reagents useful for analyzing the protein-protein interface between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments of the present disclosure, the target and / or presenter protein is an intracellular protein. In some embodiments, the target and / or presenter protein is a mammalian protein.

The invention provides a method for recovering a cyclosporine crude product from production waste liquid and the cyclosporine crude product, and relates to the technical field of chemical separation engineering. The method for recovering the cyclosporine crude product from the production waste liquid comprises the following steps: concentrating the waste liquid; primary crystallization; and performing secondary crystallization and drying. According to the method for recovering the cyclosporine crude product from the production waste liquid, 45%-65% of cyclosporine in the waste liquid can be recovered, and the method is very economical, practical and suitable for industrial production. According to the method, cyclosporine in the waste liquid is recycled, the recycled cyclosporine crude product can be put into cyclosporine refining production, the production cost of cyclosporine can be greatly reduced, and the method is simple in process route, small in material consumption and small in three-waste emission, and meets the requirements of economic, environmental and social progress.

The present invention relates to cyclosporin compositions and methods of use. The present invention discloses a compound having a structure of formula I: (I) a stereoisomer thereof, or a pharmaceutically acceptable salt of any one of the compound or the stereoisomer thereof; wherein: L1 is a C1 to C4 alkylene group optionally substituted by one or more F; r is PEG having 40 to 50 ethylene oxide units, wherein the PEG comprises a linker L2; and L2 is a C1-6 unsubstituted heteroalkylene group having one or two nitrogen atoms. The present invention also discloses the use of the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt of any one of the compound or the stereoisomer thereof in the preparation of a medicament for treating a disease associated with neutrophil-mediated inflammation in a target tissue of a mammalian subject in need thereof.

Compositions are disclosed that include acridinium esters of cyclosporin A or C. Kits containing same, as well as methods of making and using same, are also disclosed.